Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Could Contentious IPR Trade Terms Bloat Healthcare Costs, Sink Pharma’s Image?

Executive Summary

Intellectual property rights terms in various trade agreements could have serious ramifications not just on healthcare costs but also on the legitimate trade of generic drugs between developing nations, say some experts. Pharma’s image may be at stake too.

You may also be interested in...



US Mulls TPP Re-entry, Critiques Japan Reforms

President Trump has indicated the US may be interested in rejoining the Trans-Pacific Partnership free trade talks, but there would be multiple obstacles, not least whether strict US conditions could be met, including in the pharma IPR area. PhRMA meanwhile voices concerns over recent Japanese reforms.

India Facing ‘Pincer-Like’ Pressure On IP In Europe, Asia Trade Talks

Humanitarian group MSF says India is facing “pincer-like pressure” to relax its strict patent laws in order to conclude free trade deals in Europe and Asia, and is calling on New Delhi to stand firm.

Canada To Have Patent Term Extensions Soon – And An Export Waiver

A bill implementing the provisions of the EU-Canada CETA trade deal is expected to be approved soon, bringing a new Certificate of Supplementary Protection together with an export manufacturing waiver, and some changes to the patent litigation system.

Related Content

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel